Eurocine Vaccines discloses interim report for July 2022 – March 2023
Eurocine Vaccines AB (publ) (“Eurocine Vaccines” or the “Company”) hereby discloses the interim report for July 2022 to March 2023. Below is a summary of the report. The full report is available on Eurocine Vaccines’ website and as an attachment.2023-01-01 – 2023-03-31 (third quarter) · Results after tax for the quarter amounted to -3.2 MSEK (-5.6 MSEK) · Revenues for the quarter amounted to 2 KSEK (0 KSEK) · Earnings per share for the quarter amounted to -0.115 SEK (-0.397 SEK) 2022-07-01 – 2023-03-31 (nine-month period) · Results after